Gilpin Wealth Management’s Definium Therapeutics DFTX Stock Holding History

Gilpin Wealth Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-6	Closed	-$283	–	1457
2026 Q2	$283	Buy	+6	New	+$148	﹤0.01%	839

Other funds holding DFTX

Stableford Capital II Scottsdale, Arizona $288M AUM 21.3% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Bullock Wealth Management Bloomington, Indiana $241M AUM 23.31% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Gilpin Wealth Management's DFTX Position: Q3 2026 in Review

Gilpin Wealth Management sold out of Definium Therapeutics (DFTX) in Q3 2026, closing a stake of 6 shares — an estimated $283 sold.

Gilpin Wealth Management first reported a position in DFTX in Q2 2026 and held it in 1 quarter. The position peaked at $283 in Q2 2026. 8 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

Gilpin Wealth Management reported no remaining Definium Therapeutics position as of Q3 2026 after selling out during the quarter.
Gilpin Wealth Management sold 6 Definium Therapeutics shares in Q3 2026, an estimated $283.
Gilpin Wealth Management first reported a position in Definium Therapeutics in Q2 2026 and held it in 1 quarter.
Gilpin Wealth Management's Definium Therapeutics position peaked at $283 in Q2 2026.
8 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.